Lab21 and BreastHealth UK Form Partnership for Breast Health Management

BreastHealth UK (BHUK) and Lab21 announced they have established a partnership to offer UK women state-of-the-art personalized health management and predictive genetic testing for breast cancer risk. The partnership provides patients with high quality laboratory diagnostic services to support the expanding portfolio of diagnostic and breast screening services. BreastHealth UK is launching a new approach to screening called the ‘Breast Health Risk Assessment Service’. The deCODE BreastCancer™ test, which has been validated in more than 100,000 women, will be offered as part of an overall breast cancer risk assessment that takes into account family history and lifestyle factors using the Tyrer-Cuzick model. Results will be provided in consultation with an experienced breast surgeon to interpret the results and recommend potential follow-up breast screening as required. The Myriad BRCA1 and BRCA2 genetic tests are suitable for women with a strong family history of breast cancer and specialist counselling is provided to support women that require this test. The Myriad BRCA tests are based on extensive clinical research and are currently the only tests available which address predisposition to familial (inherited) breast cancer. Troels Jordansen, CEO of BreastHealth UK, commented, “Our aim is to offer appropriate and timely breast screening to women of all ages, to ensure that breast cancer or other problems are identified and treated early. This test enables us to personalize screening programmes more accurately based on women’s individual risk scores. We are very pleased to be working with Lab21 who have an excellent track record in the delivery of these types of tests.”